Koirala, SBorisov, SDanila, EMariandyshev, AShrestha, BLukhele, NDalcolmo, MShakya, S RMiliauskas, SKuksa, LManga, SAleksa, ADenholm, J TKhadka, H BSkrahina, ADiktanas, SFerrarese, MBruchfeld, JKoleva, APiubello, AKoirala, G SUdwadia, Z FPalmero, D JMunoz-Torrico, MGc, RGualano, GGrecu, V IMotta, IPapavasileiou, ALi, YHoefsloot, WKunst, HMazza-Stalder, JPayen, M-CAkkerman, O WBernal, EManfrin, VMatteelli, AMustafa Hamdan, HNieto Marcos, MCadiñanos Loidi, JCebrian Gallardo, J JDuarte, REscobar Salinas, NGomez Rosso, RLaniado-Laborín, RMartínez Robles, EQuirós Fernandez, SRendon, ASolovic, ITadolini, MViggiani, PBelilovski, EBoeree, M JCai, QDavidavičienė, EForsman, L DDe Los Rios, JDrakšienė, JDuga, AElamin, S EFilippov, AGarcia, AGaudiesiute, IGavazova, BGayoso, RGruslys, VJonsson, JKhimova, EMadonsela, GMagis-Escurra, CMarchese, VMatei, MMoschos, CNakčerienė, BNicod, LPalmieri, FPontarelli, AŠmite, ASouleymane, M BVescovo, MZablockis, RZhurkin, DAlffenaar, J-WCaminero, J ACodecasa, L RGarcía-García, J-MEsposito, SSaderi, LSpanevello, AVisca, DTiberi, SPontali, ECentis, RD'Ambrosio, Lvan den Boom, MSotgiu, GMigliori, G B2025-01-072025-01-072021-03-19https://hdl.handle.net/10668/26663The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally. This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year. All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines. Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10-80% in the remaining 5 countries). The drug-resistance pattern of the patients was severe (>30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3-7) in the overall cohort and 6 (4-8) among patients with a final outcome). For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13-23) (in days 553 (385-678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30-90) days for the whole cohort and 60 (30-100) for patients with a final outcome and, respectively, of 55 (30-90) and 60 (30-90) days for culture conversion. Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/BedaquilineDelamanidMDR-TBPrevention of TB sequelaeTreatment outcomesTuberculosisAdultAntitubercular AgentsDiarylquinolinesFemaleHumansMaleMiddle AgedNitroimidazolesOxazolesProspective StudiesTreatment OutcomeTuberculosis, Multidrug-Resistantresearch article33753021open access10.1016/j.pulmoe.2021.02.0062531-0437https://doi.org/10.1016/j.pulmoe.2021.02.006